Skip to main content

With an increasing demand for RUCONEST® for the treatment of hereditary angioedema and an increasing need for rhC1INH in our clinical trials in new, large indications, we continue to invest in expanding our in-house processing capabilities

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline